Organon (OGN) Interest Expenses (2020 - 2026)
Organon (OGN) posted quarterly Interest Expenses of $108.0 million for Q2 2026, down 17.56% year-over-year from $131.0 million in Q2 2025, and down 2.7% on a QoQ basis from $111.0 million in Q1 2026.
Organon (OGN) Interest Expenses (2020 - 2026) Analysis & Trends
Organon has reported Interest Expenses for 6 years, with the latest figure at $108.0 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $108.0 million, down 17.56% year-over-year; the trailing twelve-month figure through Jun 2026 was $468.0 million (down 8.77% YoY), and the FY2025 annual result was $504.0 million, down 3.08% from the prior year.
- Interest Expenses eased to $108.0 million in Q2 2026, from $111.0 million in the prior quarter.
- Over five years, Interest Expenses peaked at $134.0 million in Q3 2023 and troughed at $108.0 million in Q3 2022.
- A 5-year average of $123.8 million and a median of $127.0 million in 2024 frame the typical range for Interest Expenses.
- The largest YoY upside for Interest Expenses was 82.26% in 2022 against a maximum downside of 65.61% in 2022.
- A 5-year view of Interest Expenses shows it stood at $119.0 million in 2022, then grew by 8.4% to $129.0 million in 2023, then grew by 2.33% to $132.0 million in 2024, then fell by 8.33% to $121.0 million in 2025, then fell by 10.74% to $108.0 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $108.0 million in Q2 2026, $111.0 million in Q1 2026, and $121.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 108.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.00 Mn |
| Jun 30, 2026 | 108.00 Mn |
| Mar 31, 2026 | 111.00 Mn |
| Mar 31, 2026 | 111.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Sep 30, 2025 | 128.00 Mn |
| Sep 30, 2025 | 128.00 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Mar 31, 2025 | 124.00 Mn |
| Dec 31, 2024 | 132.00 Mn |
| Dec 31, 2024 | 132.00 Mn |
| Sep 30, 2024 | 126.00 Mn |
| Sep 30, 2024 | 126.00 Mn |
| Jun 30, 2024 | 131.00 Mn |
| Jun 30, 2024 | 131.00 Mn |
| Mar 31, 2024 | 131.00 Mn |
| Mar 31, 2024 | 131.00 Mn |